再生元制药 REGN 深 沪
等待开盘 08-10 09:30:00 美东时间
784.36
+12.250
+1.59%
华盛通- 最 高785.98
- 今 开774.47
- 成交量 55.10万股
- 最 低 747.00
- 昨 收 772.11
- 总市值 8627.96万
- 52周最高 821.11
- 市盈率 静 10.90
- 换手率 500.88%
- 52周最低 541.00
- 委 比 40.21%
- 总股本 0.00亿
- 历史最高 1211.1999
- 量 比 0.52
- 振 幅 5.05%
- 历史最低 1.10
- 每 手 1
- 风险率 79.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Drops Dupixent Successor Candidate After Assessing Data
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
06-17 22:55
Critical Metals Stock Drops Despite European Lithium Deal
Critical Metals (NASDAQ: CRML) shares are dropping Monday after it signed a binding Scheme Implementation Deed to acquire European Lithium.
05-19 01:54
ReNew Reports Q4 Double Beat, Record Full-Year Net Profit
ReNew Energy Global Plc (NASDAQ: RNW) reported fourth-quarter earnings Monday before the market opened. Here's a rundown of the report.
05-18 23:01
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
Lakewood-Amedex Biotherapeutics shares were trading higher Monday but have reversed lower after the company announced data for Nu-3.
05-18 22:11
Nokia Shares Edge Higher Following Patent Victory, Management Revamp
Nokia (NYSE: NOK) shares are edging higher in Monday's pre-market as traders weigh UK patent fallout, leadership shifts, and firmer Nasdaq.
05-18 21:03
Brady Reports Q1 Earnings Beat, Raises FY26 EPS Guidance
Brady Corporation (NYSE: BRC) reported first-quarter earnings on Monday before the market opened. Here's a rundown of the report.
05-18 20:45
Market-Moving News for May 18th
REGN: -11% | Regeneron Fianlimab Combination Fails To Reach Statistical Significance In First-Line Unresectable Or Metastatic Melanoma Phase 3 Trial UNH: -6% | UnitedHealth Group shares are trading lower
05-18 19:16
Why Is Regeneron Stock Sinking Monday?
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
05-18 18:28
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
04-30 01:57
